Forbes

AI isn’t replacing doctors—it’s fixing healthcare infrastructure. Where automation works, and why VCs are betting on scalable health tech.

Longer lives are colliding with a healthcare system built for short crises. What that mismatch means for families, costs, and the future of care.

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Deere & Co's AI innovations have drawn praise from experts who say their restructuring of work holds lessons for health care and other industries.

To settle the fight over the Affordable Care Act, the Senate can do nothing, broker a short term compromise or finally tackle the core problem: rising healthcare costs

Pharmaceutical patent protection can be extended when drug companies bring newer products to market before their first patent expires

Alignment Healthcare reported its Medicare Advantage enrollment soared 31% compared to last year as larger rivals have retreated from such coverage for older adults.

“Can you — should you — keep expanding at this pace?” “Yes, we can… and yes, we should…. We would be crazy not to.”

New U.S. dietary guidelines push meat and animal-based products while underplaying plant-based vegetarian options. More balanced public health messaging may be warranted.

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers to help their workers manage obesity.

Discontinuing obesity medicines means the weight comes back and people lose the cardiovascular and metabolic benefits conferred by the drugs.

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.

ER doctor explains 2025-2026 H3N2 flu symptoms, treatment & when to go to the hospital. Get vital data on this severe flu season & also whether to get vaccinated.

Synthetic opioid deaths fell sharply in 2023 and 2024 after a shock to the fentanyl supply. New evidence points to precursor controls, not enforcement, as the key driver.